Bluebird Spins Off Oncology Business As Cell, Gene Therapy Segments Grow Apart
Gene Therapy Focus Opens Partnering, Acquisition Opportunities
Executive Summary
Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird
You may also be interested in...
Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
More Positive Data For Recordati Cushing's Drug
With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.
A BCMA Setback For Bristol And Bluebird With FDA Refuse-To-File Letter
The US FDA took issue with the CMC portion of the BLA for the BCMA-targeted therapy idecabtagene vicleucel for multiple myeloma. An approval is tied to a $9 CVR for Celgene shareholders.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports